Schroder Investment Management Group Sells 336,633 Shares of Grifols, S.A. (NASDAQ:GRFS)

Schroder Investment Management Group lowered its position in shares of Grifols, S.A. (NASDAQ:GRFS - Free Report) by 43.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 436,393 shares of the biotechnology company's stock after selling 336,633 shares during the period. Schroder Investment Management Group owned about 0.06% of Grifols worth $3,229,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of GRFS. Orion Portfolio Solutions LLC bought a new stake in Grifols during the 4th quarter worth approximately $119,000. Norges Bank bought a new position in Grifols during the fourth quarter valued at $14,434,000. Anthracite Investment Company Inc. grew its holdings in Grifols by 7.4% during the fourth quarter. Anthracite Investment Company Inc. now owns 659,964 shares of the biotechnology company's stock valued at $4,910,000 after purchasing an additional 45,410 shares during the period. Financial Engines Advisors L.L.C. bought a new position in Grifols during the fourth quarter valued at $358,000. Finally, LPL Financial LLC lifted its position in shares of Grifols by 25.0% during the fourth quarter. LPL Financial LLC now owns 75,398 shares of the biotechnology company's stock worth $561,000 after acquiring an additional 15,067 shares in the last quarter.

Wall Street Analyst Weigh In

Separately, Morgan Stanley assumed coverage on Grifols in a research note on Wednesday, February 12th. They issued an "overweight" rating on the stock.

Grifols Stock Down 4.3 %

Shares of Grifols stock traded down $0.30 during midday trading on Thursday, hitting $6.64. The company had a trading volume of 203,864 shares, compared to its average volume of 1,221,417. The company has a 50 day moving average of $7.49 and a 200 day moving average of $7.90. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26. Grifols, S.A. has a 52-week low of $5.79 and a 52-week high of $9.96. The stock has a market capitalization of $4.56 billion, a P/E ratio of 5.67 and a beta of 0.41.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.